RBC Capital Markets has lifted its price target on Biogen (BIIB) to $272 from $256, following the drugmaker's third-quarter earnings. In a note to clients, the Canadian bank said Biogen's growth story is back on track, with investors beginning to appreciate the company's drug-development pipeline—especially its Alzheimer's treatment Leqembi.
The new target implies meaningful upside from current levels, though it's not a guarantee of where the stock will go. For everyday investors, it's a signal that at least one major Wall Street firm sees more value in Biogen than the market currently does.
What's driving the optimism?
RBC's confidence centers on Leqembi, a treatment for early Alzheimer's disease developed with partner Eisai. The bank projects Leqembi's US sales will be 47% higher in 2027 compared to the prior year, and argues that the roughly $4 billion Alzheimer's revenue opportunity isn't fully reflected in Biogen's valuation.
That's a big number for a company with total revenue of around $10 billion annually. If Leqembi captures even a portion of that market, it could meaningfully change Biogen's growth trajectory.
The timing also matters. RBC points to a series of near-term milestones: an FDA advisory committee review, a potential approval decision, and then the commercial launch. Each step reduces uncertainty about whether the drug can actually reach patients at scale—and that can change how investors value the company well before sales show up in reported results.
Why milestones matter more than earnings
For biotech stocks, the biggest price moves often happen when uncertainty falls, not when revenues finally arrive. This is a key concept for investors to understand.
When a drug like Leqembi clears an advisory committee meeting and then an FDA decision, investors typically assign a higher probability to the long-term sales path. That can lead to a "re-rating" of the shares—meaning the market is willing to pay a higher multiple on earnings because the future looks more certain.
RBC's $272 target depends on those Alzheimer's milestones, not just quarterly beats. If Leqembi hits its marks, the stock could climb toward that target. If it stumbles, the downside could be sharp.
The flip side is more event risk. As those dates get closer, Biogen's stock can become more headline-driven, with larger-than-usual single-day swings that have little to do with the latest quarter. Investors should be prepared for volatility around these catalysts.
What it means for your portfolio
For everyday investors, Biogen's story is a reminder that biotech investing is often about betting on future events, not just current earnings. The company's Q3 results were solid enough to prompt RBC's upgrade, but the real value lies in the pipeline.
Leqembi is already approved in the US, but its commercial rollout has been slower than some hoped. The FDA advisory committee review and potential approval decision could expand its use or clarify its label, which would directly affect sales.
RBC's 47% growth projection for 2027 suggests the bank expects Leqembi to gain traction, but that's a forecast, not a certainty. Alzheimer's treatments have a history of regulatory and commercial hurdles, and competition is growing.
For those who own Biogen, the key is to watch the upcoming milestones. For those considering a position, it's worth understanding that the stock's fate is tied to a single drug's success—a classic biotech risk-reward profile.
As always, no single analyst's target should drive your decision. But RBC's move is a useful data point in assessing how the Street views Biogen's prospects.
In the broader market, biotech has been a mixed bag this earnings season. Some companies have beaten expectations, while others have disappointed. Biogen's story is one of cautious optimism, with the market waiting to see if Leqembi can deliver on its promise.
For now, RBC's message is clear: the growth story is back on track, but the proof will come in the milestones ahead.
